**Table 3: Any adverse event occurring in >1 patient in Cohorts 1 and 2**

<table>
<thead>
<tr>
<th>Event</th>
<th>Grade 1/2</th>
<th>Grade 3</th>
<th>Grade 4</th>
<th>Grade 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with ≥4 AE</td>
<td>5/10 (50%)</td>
<td>0/0</td>
<td>0/0</td>
<td>0/0</td>
</tr>
<tr>
<td>Anemia</td>
<td>0/0</td>
<td>0/0</td>
<td>0/0</td>
<td>0/0</td>
</tr>
<tr>
<td>Leukopenia</td>
<td>0/0</td>
<td>0/0</td>
<td>0/0</td>
<td>0/0</td>
</tr>
<tr>
<td>Lymphopenia</td>
<td>0/0</td>
<td>0/0</td>
<td>0/0</td>
<td>0/0</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>0/0</td>
<td>0/0</td>
<td>0/0</td>
<td>0/0</td>
</tr>
</tbody>
</table>

**Conclusions**

- ADP-A2AFP was associated with an acceptable safety profile with no evidence of hepatotoxicity.
- There have been no clear reports of T-cell related on-target off-tumor toxicity, and no protocol-defined DLTs.
- T-cell expansions and persistence appear to be dose-dependent, and ADP-A2AFP SPEAR T-cells were detectable in peripheral blood up to several months post infusion.
- There were transient decreases in tumor size and serum AFP in some patients, but no responses by RECIST v1.1 in these lower dose cohorts.
- The trial is currently enrolling patients in the expansion phase at a higher dose level for HCC, and these data will be included in a separate oral presentation by Dr. Bruno Sangro.

**Abbreviations**

- AE: adverse event
- AFP: alpha-fetoprotein
- Cy: cyclophosphamide
- DLT: dose-limiting toxicity
- ECOG: Eastern Cooperative Oncology Group
- FAC: fluorouracil, doxorubicin, cyclophosphamide
- G-CSF: granulocyte colony stimulating factor
- HCC: hepatocellular carcinoma
- IHC: immunohistochemistry
- JAK2: Janus Kinase 2
- KRAS: Kirsten Ras
- LDT: dose-limiting toxicity
- MGMT: O6-methylguanine-DNA methyltransferase
- PD-1: programmed death-1
- PD-L1: programmed death ligand-1
- PR: partial response
- PRGC: partial response per gastrointestinal criteria
- PFS: progression-free survival
- PD: progressive disease
- RECIST: Response Evaluation Criteria in Solid Tumors
- RR: response rate
- SD: stable disease
- SDPR: stable disease per peripheral criteria
- TCR: T-cell receptor
- TNCs: tumor necrosis factors
- XRT: radiation (x-ray) therapy
- YKL-40: a biomarker for hepatocellular carcinoma
- αvβ3: a cell surface receptor

---

**References**


---

**Acknowledgments**

The authors are grateful to the patients and families who participated in this study. We are also grateful to the members of the ADP-A2AFP steering committee and for the contribution of independent reviewers. The authors wish to acknowledge the contribution of the principal investigators and their teams, and the patients and families who participated in this study. The trial is currently ongoing and additional data will be available in the future.